TWST - Twist Bioscience Corporation
Forte Biosciences Inc., Twist Bioscience Corp., and Adaptive Biotechnologies Corp., were among the top contributors to performance. Cardinal Infrastructure Group, Inc., RBC Bearings Incorporated, and VSE Corporation were among the top detractors from performance. VSE Corporation shares detracted from performance during the quarter despite strong revenue growth, record profitability, and an improved full-year outlook.
Both of these ETFs look the part, but only one is truly the better buy for investors.
Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report)'s stock price dropped 7.4% on Friday. The stock traded as low as $134.83 and last traded at $133.8060. 180,478 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 1,711,585 shares. The stock had previously closed at $144.49. Analyst Ratings Changes
During Q3 2026, the Polen 5Perspectives Small-Mid Growth Composite Portfolio returned -12.5% (net of fees) compared to the -10.4% return of the Russell 2500 Growth Index. The top contributors to the Portfolio's relative performance in the quarter were Twist Bioscience, Twilio, and Embraer. The most significant detractors from the Portfolio's relative performance in the quarter were nLight, Terawulf, and BWX Technologies.
.Danaher (DHR), one of the world's largest providers of medical diagnostics and laboratory equipment, recently announced plans to launch its first AI-powered autonomous laboratory, scheduled to operate at commercial scale in early 2027. While market trading barely moved the stock on the announcement date, the news marks a quiet turning point for life science automation.
Forget the "Magnificent Seven" in favor of the "Tremendous Three"?
Quantum-Si (NASDAQ: QSI - Get Free Report) and Twist Bioscience (NASDAQ: TWST - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Valuation and Earnings This table compares Quantum-Si and Twist
Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report)'s share price dropped 9.7% during mid-day trading on Tuesday after an insider sold shares in the company. The company traded as low as $186.61 and last traded at $185.0970. 1,748,314 shares traded hands during trading, an increase of 8% from the average daily volume of 1,618,778 shares.
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).
Twist Bioscience Corp. (NASDAQ:TWST) shares are trading lower Friday, pulling back after touching a fresh 52-week high near $192 earlier in the session. Here's what you should know.
Louis says buy the AI dip
The biotech will both contribute to and draw from its findings. It'll also earn revenue from its participation.
Twist Bioscience Corporation (NASDAQ:TWST) on Wednesday announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Co. (NYSE:LLY).
[url="]Twist Bioscience Corporation[/url] (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collabo
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). Twist is a provider of antibody characterization data services for TuneLab, including for AbLab, an antibody developability prediction model. TuneLab was created to accelerate biotech innovation by enabling participating compan.
If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of evidence that the pace really is accelerating. We saw longer-running agents, faster and cheaper inference, AI systems reaching into laboratories and physical equipment, robots learning from fewer demonstrations, and new capital and infrastructure forming around commercial deployment.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in a fireside chat at the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026 at 1:25 pm Eastern Time in New York City. The fireside chat will be webcast live and can be accessed by visiting the “In.
Brandywine Managers LLC acquired a new position in shares of Twist Bioscience Corporation (NASDAQ: TWST) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,970 shares of the company's stock, valued at approximately $2,157,000. Twist Bioscience comprises
Deutsche Bank AG acquired a new stake in Twist Bioscience Corporation (NASDAQ: TWST) in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 90,053 shares of the company's stock, valued at approximately $9,265,000. Deutsche Bank AG owned about 0.14% of Twist
Twist Bioscience Corporation is rated Hold, as its $9.5bn valuation appears disconnected from current fundamentals, and profitability remains elusive. TWST's recent 200% stock surge is driven by AI-related news, short squeeze dynamics, and strong DSPS revenue growth, not by blowout earnings. Full-year 2026 guidance was raised to $456–$457m revenue with adjusted EBITDA breakeven targeted, but losses and elevated SG&A persist.